globenewswire news

BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026.

Upcoming Scientific Conferences:

9^th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026
Montréal, Quebec

• Presentation: Ocular Therapeutix: Retina Experience Redefined
  Presentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDT
  Presenter: Peter K. Kaiser, MD, Chief Development Officer

• Panel Title: The Impact of Recent FDA Guidance on Drug Development
  Panel Date/Time: Tuesday, July 14, 2026, 4:40 – 5:20 PM ET
  Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO

The American Society of Retina Specialists (ASRS) 44^th Annual Meeting: July 15 - 18, 2026
Montréal, Quebec

• Presentation: Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3
  SOL-1 Trial Results
  Session: Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD
  Presentation Date/Time: Thursday, July 16, 2026, 8:15 – 8:45 AM EDT
  Presenter: Dilsher S. Dhoot, MD

• Presentation: Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database
  Session: Real-world nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data
  Presentation Date/Time: Thursday, July 16, 2026, 8:50 – 8:53 AM EDT
  Presenter: Andrew A. Moshfeghi, MD, MBA, FASRS

• On-Demand Paper Title: Anti-VEGF Treatment Patterns and Long-Term Vision Outcomes in Patients with nAMD in the IRIS Registry
  Session Date/Time: On-demand papers will be continually available for viewing throughout the meeting
  Presenter: Priya Vakharia, MD

• Symposium Title: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  Session: Satellite Symposia
  Symposium Date/Time: Thursday, July 16, 2026, 6:00 – 7:30 PM EDT
  Faculty: Arshad M. Khanani, MD; Dilsher S. Dhoot, MD; Mark R. Barakat, MD; Peter K. Kaiser, MD, Chief Development Officer; and Jeffrey S. Heier, MD, Chief Scientific Officer

Exact medical conference presentation times may be subject to change.

Upcoming Investor Conference:

HC Wainwright 6^th Annual Ophthalmology Virtual Conference:
Date: Wednesday, July 22, 2026
Fireside Chat: 4:30 – 5:00 PM EDT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: Virtual

A live webcast of the fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days following the presentation.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com